Emerging Treatment Options for Familial Hypercholesterolemia– Review the underlying genetic mutations and the role of genetic screening for heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH) as it relates to diagnosis and treatment of familial hypercholesterolemia and in response to statins, ezetimibe and proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody treatment.
Discuss the emerging evidence on genetic mutations and their potential therapeutic significance in the development of novel low-density lipoprotein cholesterol (LDL-C) targets.
Identify the relationship of LDL-C reduction and cardiovascular disease (CVD) risk reduction including the risk in HeFH and HoFH.
Discuss the clinical presentation and implications of HeFH and the use of optimal LDL-C target goals for these patients based on current consensus recommendations.
1.0 Free CEUs for Nurse Practitioners which includes 0.75 Hours of Pharmacology
This course also offers Free CME for Physicians, PAs, and Nurses